189 related articles for article (PubMed ID: 32297279)
1. Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment.
Capelli D; Saraceni F; Fiorentini A; Chiarucci M; Menotti D; Poloni A; Discepoli G; Leoni P; Olivieri A
Adv Ther; 2020 May; 37(5):2288-2302. PubMed ID: 32297279
[TBL] [Abstract][Full Text] [Related]
2. Mobilization-driven postconsolidation therapy in elderly patients with acute myeloid leukemia: feasibility and efficacy of autologous stem cell transplantation versus low-dose gemtuzumab ozogamicin.
Capelli D; Chiarucci M; Poloni A; Saraceni F; Mancini G; Trappolini S; Troiani E; Montanari M; Scortechini I; Offidani M; Rupoli S; Scortechini AR; Gini G; Discepoli G; Leoni P; Olivieri A
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1399-406. PubMed ID: 24880020
[TBL] [Abstract][Full Text] [Related]
3. Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.
Candoni A; Papayannidis C; Martinelli G; Simeone E; Gottardi M; Iacobucci I; Gherlinzoni F; Visani G; Baccarani M; Fanin R
Am J Hematol; 2018 May; 93(5):655-663. PubMed ID: 29396857
[TBL] [Abstract][Full Text] [Related]
4. A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients.
Olivieri A; Capelli D; Troiani E; Poloni A; Montanari M; Offidani M; Discepoli G; Leoni P
Exp Hematol; 2007 Jul; 35(7):1074-82. PubMed ID: 17588476
[TBL] [Abstract][Full Text] [Related]
5. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
[TBL] [Abstract][Full Text] [Related]
6. High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
Guolo F; Minetto P; Clavio M; Miglino M; Di Grazia C; Ballerini F; Pastori G; Guardo D; Colombo N; Kunkl A; Fugazza G; Rebesco B; Sessarego M; Lemoli RM; Bacigalupo A; Gobbi M
Am J Hematol; 2016 Aug; 91(8):755-62. PubMed ID: 27084986
[TBL] [Abstract][Full Text] [Related]
7. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
Ravandi F; Assi R; Daver N; Benton CB; Kadia T; Thompson PA; Borthakur G; Alvarado Y; Jabbour EJ; Konopleva M; Takahashi K; Kornblau S; DiNardo CD; Estrov Z; Flores W; Basu S; Allison J; Sharma P; Pierce S; Pike A; Cortes JE; Garcia-Manero G; Kantarjian HM
Lancet Haematol; 2019 Sep; 6(9):e480-e488. PubMed ID: 31400961
[TBL] [Abstract][Full Text] [Related]
8. Gemtuzumab Ozogamicin in
Schlenk RF; Paschka P; Krzykalla J; Weber D; Kapp-Schwoerer S; Gaidzik VI; Leis C; Fiedler W; Kindler T; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Horst HA; Koller E; Wulf G; Schleicher J; Bentz M; Greil R; Hertenstein B; Krauter J; Martens U; Nachbaur D; Abu Samra M; Girschikofsky M; Basara N; Benner A; Thol F; Heuser M; Ganser A; Döhner K; Döhner H
J Clin Oncol; 2020 Feb; 38(6):623-632. PubMed ID: 31851556
[TBL] [Abstract][Full Text] [Related]
9. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
de Witte T; Suciu S; Meert L; Halkes C; Selleslag D; Bron D; Amadori S; Willemze R; Muus P; Baron F
Ann Hematol; 2015 Dec; 94(12):1981-9. PubMed ID: 26410352
[TBL] [Abstract][Full Text] [Related]
10. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
[TBL] [Abstract][Full Text] [Related]
11. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
[TBL] [Abstract][Full Text] [Related]
12. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.
Brunnberg U; Mohr M; Noppeney R; Dürk HA; Sauerland MC; Müller-Tidow C; Krug U; Koschmieder S; Kessler T; Mesters RM; Schulz C; Kosch M; Büchner T; Ehninger G; Dührsen U; Serve H; Berdel WE
Ann Oncol; 2012 Apr; 23(4):990-6. PubMed ID: 21810729
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML.
Bassan R; Intermesoli T; Masciulli A; Pavoni C; Boschini C; Gianfaldoni G; Marmont F; Cavattoni I; Mattei D; Terruzzi E; De Paoli L; Cattaneo C; Borlenghi E; Ciceri F; Bernardi M; Scattolin AM; Todisco E; Campiotti L; Corradini P; Cortelezzi A; Ferrero D; Zanghì P; Oldani E; Spinelli O; Audisio E; Cortelazzo S; Bosi A; Falini B; Pogliani EM; Rambaldi A
Blood Adv; 2019 Apr; 3(7):1103-1117. PubMed ID: 30948365
[TBL] [Abstract][Full Text] [Related]
15. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
[TBL] [Abstract][Full Text] [Related]
16. The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.
Chen Y; Yang T; Zheng X; Yang X; Zheng Z; Zheng J; Liu T; Hu J
Medicine (Baltimore); 2016 Jul; 95(30):e4182. PubMed ID: 27472687
[TBL] [Abstract][Full Text] [Related]
17. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
Thomas X; Suciu S; Rio B; Leone G; Broccia G; Fillet G; Jehn U; Feremans W; Meloni G; Vignetti M; de Witte T; Amadori S
Haematologica; 2007 Mar; 92(3):389-96. PubMed ID: 17339189
[TBL] [Abstract][Full Text] [Related]
18. Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in acute myeloid leukemia patients.
Muresan B; Mamolo C; Cappelleri JC; Mokgokong R; Palaka A; Soikkeli F; Heeg B
Future Oncol; 2021 Aug; 17(22):2883-2892. PubMed ID: 33858190
[TBL] [Abstract][Full Text] [Related]
19. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
[TBL] [Abstract][Full Text] [Related]
20. A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
Bergua JM; Montesinos P; Martinez-Cuadrón D; Fernández-Abellán P; Serrano J; Sayas MJ; Prieto-Fernandez J; García R; García-Huerta AJ; Barrios M; Benavente C; Pérez-Encinas M; Simiele A; Rodríguez-Macias G; Herrera-Puente P; Rodríguez-Veiga R; Martínez-Sánchez MP; Amador-Barciela ML; Riaza-Grau R; Sanz MA;
Br J Haematol; 2016 Sep; 174(5):700-10. PubMed ID: 27118319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
